Actinic Keratosis Market Report 2026

The actinic keratosis market size has grown strongly in recent years. It will grow from $8.42 billion in 2025 to $8.91 billion in 2026 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to rising uv exposure and sunburn incidence, limited availability of effective topical agents, increasing skin cancer prevalence, growing dermatology infrastructure, adoption of conventional surgical procedures.

The actinic keratosis market size is expected to see strong growth in the next few years. It will grow to $11.06 billion in 2030 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to development of advanced photodynamic therapies, increasing use of combination topical and procedural treatments, expansion of hospital and dermatology clinic networks, rising consumer awareness of early intervention, introduction of innovative homecare treatment solutions. Major trends in the forecast period include increasing awareness about sun protection and skin health, rising adoption of non-invasive photodynamic therapy, growth in topical therapeutics usage for early-stage ak, expansion of dermatology clinics and homecare treatments, increasing preference for combination therapies.

The rising incidence of severe sunburns is expected to drive the growth of the actinic keratosis market in the coming years. Severe sunburns are intense skin burns caused by overexposure to ultraviolet (UV) radiation, resulting in redness, pain, swelling, and sometimes blistering. Factors contributing to sunburns include prolonged UV exposure, inadequate sun protection, increased outdoor activities during peak UV hours, and rising temperatures due to climate change. Sunburns contribute to actinic keratosis by damaging DNA in skin cells through UV radiation, causing mutations that disrupt normal cell function and lead to the formation of precancerous lesions, particularly with repeated or prolonged sun exposure. For instance, in May 2024, Melanoma Focus, a UK-based charity, reported that in 2022-23, there were 201 hospital admissions due to sunburn, including 89 children and 25 infants under one year old. The charity also found that 66% of UK adults aged 16-65 recalled getting sunburned as children, with 65% experiencing severe sunburn with blisters at least once, rising to 77% among those with light, pale, or white skin. Therefore, the increasing incidence of severe sunburns is driving the growth of the actinic keratosis market.

Major companies operating in the actinic keratosis market are focusing on developing topical ointments to effectively target and remove precancerous lesions, reduce recurrence rates, and improve patient compliance through shorter treatment durations and enhanced safety profiles. Topical ointments are medicated creams or gels applied directly to affected skin, containing active ingredients such as tirbanibulin, which target abnormal keratinocytes to treat precancerous lesions. For instance, in June 2024, Almirall SA, a Spain-based biopharmaceutical company, received approval from the US Food and Drug Administration (FDA) for a supplemental new drug application (sNDA) to expand the use area for its drug, Klisyri, to up to 100 cm². Klisyri (tirbanibulin) 1% ointment is a microtubule inhibitor designed to prevent the proliferation of abnormal keratinocytes, effectively reducing the number and size of precancerous lesions for the treatment of actinic keratosis (AK) on the face or scalp.

In June 2024, Sun Pharmaceutical Industries Limited, an India-based pharmaceutical company, merged with Taro Pharmaceutical Industries Ltd. for $454 million. Through this merger, Sun Pharmaceutical Industries Limited aims to leverage Taro’s expertise in dermatology and pediatrics, along with specialty and generic pharmaceuticals and over-the-counter products. Taro Pharmaceutical Industries Ltd. is an Israel-based pharmaceutical company focused on developing and manufacturing dermatology and topical treatment products, including actinic keratosis therapies.

Major companies operating in the actinic keratosis market are Galderma SA, LEO Pharma A/S, Almirall S.A., Bausch Health Companies Inc., Perrigo Company plc, Pfizer Inc, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Novartis AG, GSK plc, Amgen Inc., Incyte Corporation, Aclaris Therapeutics Inc., Biofrontera AG, Hill Dermaceuticals Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Viatris Inc.

North America was the largest region in the actinic keratosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the actinic keratosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the actinic keratosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the actinic keratosis market by increasing costs for imported topical agents, photodynamic therapy equipment, and surgical instruments. Segments such as topical treatment creams and photodynamic therapy devices are most affected, particularly in north america, europe, and asia-pacific regions that rely heavily on imports. This has led to higher treatment costs and delayed equipment availability. On the positive side, tariffs have encouraged local manufacturing of therapeutics and devices, promoting domestic production and innovation in treatment solutions.

The actinic keratosis market research report is one of a series of new reports that provides actinic keratosis market statistics, including actinic keratosis industry global market size, regional shares, competitors with a actinic keratosis market share, detailed actinic keratosis market segments, market trends and opportunities, and any further data you may need to thrive in the actinic keratosis industry. This actinic keratosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Actinic keratosis (AK), also known as solar keratosis, is a common precancerous skin condition caused by prolonged exposure to ultraviolet (UV) radiation from the sun or artificial sources. It results in rough, scaly, or crusty patches on sun-exposed areas such as the face, scalp, hands, and arms. AK is considered an early stage of squamous cell carcinoma (SCC) and requires treatment to prevent progression. Regular skin checks and protection from UV exposure are essential for managing and preventing actinic keratosis.

The main treatment types for actinic keratosis include topical treatments, surgical procedures, photodynamic therapy, and others. Topical treatments involve applying creams or ointments directly to the affected areas of the skin. These treatments are distributed through channels such as hospital pharmacies, drug stores and retail pharmacies, and online providers. End users include hospitals, dermatology clinics, spas and rejuvenation centers, homecare settings, and others.

The actinic keratosis market consists of revenues earned by entities by providing services such as skin cancer screenings, cryotherapy, laser treatments, patient education programs and other medical procedures or products for prevention and management. The market value includes the value of related goods sold by the service provider or included within the service offering. The actinic keratosis market also includes sales of cryosurgery devices, laser treatment systems, and sunscreen products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.